MedTrace Logo

Pregabalin in the Prevention of Postoperative Delirium and Pain

NCT00819988 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2012-01-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether administration of pregabalin by mouth immediately preoperatively and three times daily for 3 days after surgery reduces the incidence of delirium postoperatively and improves overall pain control.

Conditions

Interventions

DRUG

Pregabalin

Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function

OTHER

Sugar pill

Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Alan J Chaput, MD, MSc · The Ottawa Hospital

  • Homer Yang, MD · The Ottawa Hospital

  • Gregory L Bryson, MD, MSc · The Ottawa Hospital

  • Holly Evans, MD · The Ottawa Hospital

  • Paul Beaule, MD · The Ottawa Hospital

  • Prasad Jetty, MD · The Ottawa Hospital

  • Barbara Power, MD · The Ottawa Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2011-09-30
Completion
2011-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00819988 on ClinicalTrials.gov